This Week in Surgery — Jul 3, 2026

Welcome to This Week in Surgery. This week we are covering ten notable papers spanning three major clinical themes: advances in minimally invasive abdominal and colorectal surgery, the continued de-escalation of axillary management in breast surgical oncology, and strategies to optimize the perioperative window for complex oncologic resections. Let us dive in.

We begin with a look at how minimally invasive techniques continue to redefine standard abdominal and colorectal procedures, offering clear recovery advantages while introducing distinct technical challenges. In a meta-analysis published in Surgical Endoscopy, Kessler and colleagues evaluated thirty-three randomized controlled trials involving over thirty-seven hundred patients to compare access routes and anastomotic techniques for right-sided colonic resections [1]. The researchers found that while open surgery offered a shorter operating time by roughly thirty-nine minutes, it significantly increased overall postoperative complications by nearly eighty percent and prolonged hospital stays. When comparing anastomotic techniques, an extracorporeal approach was about thirteen minutes faster than an intracorporeal anastomosis, but it was associated with a threefold increase in postoperative surgical site infections and slightly longer hospital stays. Interestingly, the meta-analysis found no significant differences when comparing hand-sewn versus stapled, end-to-end versus side-to-side, or isoperistaltic versus antiperistaltic configurations. For the practicing surgeon, these findings provide level one-a evidence strongly supporting a laparoscopic approach with an intracorporeal anastomosis, while allowing the surgeon to choose the specific anastomotic configuration based on personal preference and anatomical factors. This preference for minimally invasive techniques is mirrored in the management of acute surgical emergencies. Also in Surgical Endoscopy, Zafra Escalante and colleagues conducted a systematic review and meta-analysis of fifteen studies, including over twenty-two thousand patients, comparing laparoscopic and open adhesiolysis for adhesive small bowel obstruction [2]. The analysis revealed that in selected patients, a laparoscopic approach was associated with a highly significant three-fold reduction in postoperative mortality and a halving of overall postoperative complications. Patients undergoing laparoscopy also experienced a shorter hospital stay by about three and a half days and, notably, a shorter operative time of about thirty-four minutes. While the authors caution that the overall certainty of the evidence remains low to very low due to the retrospective nature of most included studies, these findings suggest that laparoscopy should be strongly considered as the initial approach for adhesive small bowel obstruction when patient selection and local expertise permit. Moving from the bowel to the abdominal wall, the debate between minimally invasive and open approaches is also active in complex ventral hernia repair. Klewitz and colleagues, writing in Surgical Endoscopy, compared the extended totally extraperitoneal plasty Rives-Stoppa retromuscular repair, known as eTEP, with the traditional open Rives-Stoppa repair in a propensity-score matched cohort of one hundred and sixty-six patients [8]. The investigators noted a clear learning curve, with significant improvements in operative time and complications occurring after the first sixty eTEP cases. In the steady-state phase, the eTEP approach required a longer operating time of one hundred and sixty minutes compared to one hundred and thirty-five minutes for the open repair. However, this investment of time in the operating room translated to a significantly shorter hospital stay, reducing the median stay from seven days to just four days, and resulted in lower postoperative pain scores on days two and three. Importantly, there were no differences in complications, hernia recurrence rates, or long-term quality of life between the two groups, confirming that eTEP is a highly effective, less painful option for medium to large ventral hernias once the initial learning curve is overcome.

Next, we turn to breast surgical oncology, where the overriding theme is the safe de-escalation of axillary surgery and the refinement of multidisciplinary care, even in complex or young patient populations. A study by Boyle and colleagues published in the Annals of Surgical Oncology utilized the National Cancer Database to analyze trends in over ninety-six thousand young breast cancer patients aged forty and under [4]. Comparing historical cohorts from 2005 to 2009 against those from 2015 to 2019, the researchers observed a dramatic shift toward axillary de-escalation. The rate of axillary lymph node dissections fell from nearly thirty-eight percent to just over nineteen percent, accompanied by a corresponding increase in the use of adjuvant radiation. This trend was especially pronounced in node-positive patients undergoing mastectomy, where axillary dissection rates plummeted from seventy-two percent to thirty-seven percent, while radiation rates rose from fifty-nine percent to seventy-six percent. Interestingly, despite this axillary de-escalation, the rate of partial mastectomies actually decreased from forty-one percent to thirty percent, while nipple-sparing mastectomies grew from less than one percent to nearly ten percent, reflecting a parallel trend toward more complex reconstructive breast operations in young women. To help clinicians safely implement this axillary de-escalation, James and colleagues published a study in the World Journal of Surgery validating and developing prediction models for sentinel lymph node metastasis in over one thousand clinically node-negative early breast cancer patients [10]. They externally validated the Memorial Sloan Kettering and MD Anderson nomograms, and developed a cohort-derived generalized linear model and a logistic ensemble model. The cohort-derived model demonstrated excellent discrimination, with an area under the curve of zero point eight three. Crucially, at a predicted risk threshold of five percent or less, the logistic ensemble model successfully classified thirty-seven percent of patients as low-risk, with an observed macrometastasis rate of only two and a half percent and a false-negative rate of just under six percent. These risk-adapted prediction tools provide a robust, data-driven framework that may allow surgeons to confidently omit sentinel lymph node biopsy altogether in a substantial subset of low-risk, node-negative patients. When an axillary lymph node dissection is unavoidable, immediate lymphatic reconstruction, or ILR, has emerged as a key technique to mitigate the risk of lymphedema. However, surgeons often worry whether performing a sentinel lymph node biopsy or targeted axillary dissection prior to the completion dissection compromises the technical success of this reconstruction. Addressing this concern, Johnson and colleagues published a retrospective database review in the Annals of Surgical Oncology evaluating over eight hundred and sixty patients undergoing axillary dissection with planned immediate lymphatic reconstruction [7]. The overall technical success rate of the reconstruction was exceptionally high at over ninety-three percent, and this rate did not differ significantly whether the staging was done concurrently or as a separate, staged procedure. The median number of reconstructed lymphatic channels was two, and the most common reasons for failure were the inability to identify blue lymphatic channels or the absence of suitable recipient veins. These findings reassure surgical oncologists that deferring the decision for a completion axillary dissection to wait for final pathology does not compromise the feasibility or technical success of immediate lymphatic reconstruction. Special clinical scenarios in breast oncology require highly structured, multidisciplinary decision-making, as highlighted by a comprehensive review of pregnancy-associated breast cancer by Venkatesh and colleagues in the Annals of Surgical Oncology [6]. The authors present a practical, trimester-based framework to guide the surgical team. During the first trimester, mastectomy is generally preferred because chemotherapy and radiation are contraindicated during fetal organogenesis. In the second and early third trimesters, breast-conserving therapy becomes a viable option because adjuvant radiation can be safely deferred until the postpartum period, and anthracycline- or taxane-based chemotherapy can be administered during pregnancy. The review emphasizes that endocrine therapy, HER2-directed therapy, immunotherapy, and blue dyes are strictly contraindicated during pregnancy, though sentinel lymph node biopsy using technetium-99m sulfur colloid is safe. By adhering to this structured, subtype-specific, and trimester-based framework, clinicians can achieve maternal oncologic outcomes that closely mirror those of non-pregnant patients.

Our final theme explores how we can optimize the perioperative window for complex oncologic resections, focusing on prehabilitation, neoadjuvant strategies, and advanced prognostic modeling. In the Annals of Surgical Oncology, Liu and colleagues presented findings from a cohort study evaluating a personalized, multimodal prehabilitation program for patients undergoing curative-intent surgery for gastroesophageal cancer [5]. The prehabilitation protocol combined medical, physical, nutritional, and psychological optimization. Compared to a historical control group, patients who completed prehabilitation experienced a dramatic halving of postoperative respiratory complications, from forty-four percent down to twenty-one percent. They also had significantly fewer cardiac, hepatic, and renal complications, shorter intensive care and hospital stays, and a substantially higher rate of successfully receiving adjuvant chemotherapy, rising from fifty-one percent to over eighty percent. Multivariate analysis confirmed that prehabilitation, rather than the specific surgical technique used, was the primary driver of these improved outcomes, making a strong case for integrating structured prehabilitation into routine perioperative pathways for upper gastrointestinal cancers. The optimization of the oncologic window is also evolving through the use of preoperative systemic therapy in colon cancer. A narrative review by Dottorini and colleagues in the Annals of Surgical Oncology evaluated the implementation of neoadjuvant chemotherapy for resectable, locally advanced colon cancer, focusing on data from key trials like FOxTROT and OPTICAL [3]. The landmark FOxTROT trial demonstrated that six weeks of preoperative chemotherapy reduced the rate of residual or recurrent disease at two years from twenty-one point five percent to sixteen point nine percent, and significantly improved tumor downstaging and complete resection rates without increasing serious postoperative complications. Similarly, the OPTICAL trial reported improved pathologic response and a significant overall survival benefit, although disease-free survival did not reach statistical significance. The authors conclude that neoadjuvant chemotherapy is highly feasible and biologically active in colon cancer, but emphasize that its success relies entirely on accurate radiological staging to select patients with truly locally advanced disease who will benefit most. Finally, prognosticating long-term outcomes before surgery can help tailor post-operative surveillance and adjuvant strategies. In a study published in the Annals of Surgical Oncology, Dong and colleagues evaluated whether baseline hepatic function, measured by the preoperative aspartate aminotransferase-to-platelet ratio index plus albumin-bilirubin score, known as the APRI plus ALBI score, could predict long-term survival in patients undergoing liver resection for biliary tract cancer [9]. Analyzing over six hundred patients, they found that a high preoperative score, indicating poorer baseline liver function, was not only associated with higher rates of posthepatectomy liver failure and ninety-day mortality, but also independently predicted significantly worse median overall survival and recurrence-free survival. Specifically, overall survival was forty months in the high-score group compared to sixty-three months in the low-score group. This association persisted even after direct propensity matching for tumor type, stage, and patient age, suggesting a profound, biologically relevant link between baseline hepatic functional reserve and long-term oncologic outcomes that extends far beyond immediate perioperative risk.

If you only have time for one paper this week, make it the meta-analysis on right-sided colonic resections by Kessler and colleagues in Surgical Endoscopy [1]. This study provides definitive, level one-a evidence resolving key surgical debates by demonstrating that a laparoscopic approach combined with an intracorporeal anastomosis minimizes postoperative complications and surgical site infections, while establishing that the specific anastomotic configuration can be safely left to surgeon preference.

Here are the key takeaways from this week in Surgery.

First, for right-sided colonic resections, level one-a evidence supports a laparoscopic approach with an intracorporeal anastomosis to reduce postoperative complications and surgical site infections, while the choice of hand-sewn versus stapled or peristaltic orientation does not impact outcomes.

Second, in selected patients with adhesive small bowel obstruction, a laparoscopic approach is associated with a three-fold reduction in mortality and a halving of postoperative complications, suggesting it should be the preferred initial approach when expertise is available.

Third, axillary surgery in young breast cancer patients is rapidly de-escalating, and new ensemble prediction models can safely identify more than a third of node-negative patients who have a very low risk of macrometastasis, supporting the selective omission of sentinel lymph node biopsy.

Fourth, performing immediate lymphatic reconstruction concurrently or as a staged procedure after axillary staging does not affect its ninety-three percent technical success rate, allowing surgeons to wait for final pathology without compromising reconstructive outcomes.

Fifth, structured, multimodal prehabilitation for gastroesophageal cancer surgery significantly reduces respiratory and other major complications, shortens hospital stays, and dramatically improves a patient's ability to tolerate subsequent adjuvant chemotherapy.

That's your roundup for This Week in Surgery. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.